T. Inoue et al., BIODISTRIBUTION STUDIES ON L-3-[FLUORINE-18]FLUORO-ALPHA-METHYL TYROSINE - A POTENTIAL TUMOR-DETECTING AGENT, The Journal of nuclear medicine, 39(4), 1998, pp. 663-667
Iodine-123-alpha-methyl tyrosine has proven to be a promising SPECT ag
ent for imaging amino acid uptake in tumors. We developed L-[3-F-18]-a
lpha-methyl tyrosine (FMT) for PET studies. The aim of this study was
to investigate its potential use as a tumor-detecting agent by using t
umor-bearing mice, Methods: We investigated the biodistribution in nor
mal BALB/C mice and BALB/cA nude mice bearing human rectal cancer cell
line (LS180) until 120 min postinjection. FMT tumor uptake at 60 min
postinjection in mice with LS180 rectal cancer, RPMI1788 B-cell lympho
ma and MCF7 mammary cell carcinoma was assessed, and the results were
compared with F-18-fluoro-2-deoxy-D-glucose (FDG) tumor uptake. The ef
fect of competitive inhibition of large neutral amino acid transport s
ystem using unlabeled L-alanine was also investigated. Results: The am
ount of FMT in blood fell to 1.05%ID/20 g at 60 min postinjectjon, whe
reas that in the pancreas was 15.2%ID/20 g, resulting in a high pancre
as-to-blood ratio of 14.5. In other organs, initial uptake peaked at 5
min postinjection and then declined with time. In LS180 tumor-bearing
mice, peak FMT uptake in tumor was observed at 60 min postinjection.
Tumor-to-blood and tumor-to-muscle ratios ranged from 1.60 to 2.94 and
from 2.79 to 3.25 over the 120-min observation period. Tumor uptake o
f FMT was clearly reduced by inhibition of the amino acid transport sy
stem. In mice with LS180 and MCF7 tumors, FMT tumor uptake at 60 min p
ostinjection was significantly higher than FDG tumor uptake, whereas i
n RPMI1788 lymphoma, uptake of FDG was significantly higher than FMT t
umor uptake, Tumor-to-blood ratios of FMT in mice with LS180, RPMI1788
and MCF7 tumor at 60 min postinjection were 1.82, 5.88 and 3.56, resp
ectively. Conclusion: FMT, like other fluorinated amino acids, may bec
ome a promising tumor-detecting agent for PET, assuming that efficient
methods of radiosynthesis are developed.